Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement

Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.


Body Mass Index Influences the Response to Infliximab in Ankylosing Spondylitis.

Ottaviani1,  Sébastien, Allanore2,  Yannick, Tubach3,  Florence, Pasquet3,  Blandine, Meyer4,  Olivier, Dieude5,  Philippe

APHP, Paris, France
Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France
APHP, Hôpital Bichat, Paris, France
Hopital Bichat, Paris, France
APHP, Hopital Bichat, Paris, France

Background/Purpose:

The excess of adipose tissue in obese individuals may have immunomodulating properties and pharmacokinetics consequences. The aim of this study was to determine whether body mass index (BMI) affects response to infliximab (IFX) in ankylosing spondylitis (AS) patients.

Methods:

In 155 patients retrospectively included with active AS, the BMI was calculated before initiation of IFX treatment (5 mg/kg intravenously). After 6 months of treatment, change from baseline in BASDAI, VAS pain, CRP level and total dose of NSAID was dichotomized with a threshold corresponding to a decrease of 50% of initial level of the measure, into binary variables assessing response to IFX (namely, VAS50, CRP50, NSAID50). Whether BMI was predictive of response to therapy according to theses different definitions was assessed with logistic regression.

Results:

Multivariate analysis revealed that a lower BMI was associated with a positive BASDAI50 response after 6 month of IFX therapy (P= 0.0003). When analyses were performed according to the 3 WHO BMI categories, similar results were observed when response to IFX was defined by BASDAI50 (P < 0.0001), VAS50 (P < 0.0001), CRP50 (P= 0.0279) and NSAID50 (P= 0.0077).

Conclusion:

This study provides the first evidence that a higher BMI negatively influences the response to IFX in AS. These data are in line with recent findings observed in rheumatoid arthritis. They raise the points of the consideration of BMI to assess to response to IFX and the pharmacological impact of fat tissue.

To cite this abstract, please use the following information:
Ottaviani, Sébastien, Allanore, Yannick, Tubach, Florence, Pasquet, Blandine, Meyer, Olivier, Dieude, Philippe; Body Mass Index Influences the Response to Infliximab in Ankylosing Spondylitis. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :530
DOI:

Abstract Supplement

Meeting Menu

2011 ACR/ARHP